Integrative Physiology

Apelin Enhances Cardiac Neovascularization After Myocardial Infarction by Recruiting Aplnr+ Circulating CellsNovelty and Significance

Dennie Tempel, Martine de Boer, Elza D. van Deel, Remco A. Haasdijk, Dirk J. Duncker, Caroline Cheng, Stefan Schulte-Merker, Henricus J. Duckers
https://doi.org/10.1161/CIRCRESAHA.111.262097
Circulation Research. 2012;111:585-598
Originally published August 16, 2012

Jump to

Abstract

Rationale: Neovascularization stimulated by local or recruited stem cells after ischemia is a key process that salvages damaged tissue and shows similarities with embryonic vascularization. Apelin receptor (Aplnr) and its endogenous ligand apelin play an important role in cardiovascular development. However, the role of apelin signaling in stem cell recruitment after ischemia is unknown.

Objective: To investigate the role of apelin signaling in recruitment after ischemia.

Methods and Results: Aplnr was specifically expressed in circulating cKit+/Flk1+ cells but not in circulating Sca1+/Flk1+ and Lin+ cells. cKit+/Flk1+/Aplnr+ cells increased significantly early after myocardial ischemia but not after hind limb ischemia, indicative of an important role for apelin/Aplnr in cell recruitment during the nascent biological repair response after myocardial damage. In line with this finding, apelin expression was upregulated in the infarcted myocardium. Injection of apelin into the ischemic myocardium resulted in accelerated and increased recruitment of cKit+/Flk1+/Aplnr+ cells to the heart. Recruited Aplnr+/cKit+/Flk1+ cells promoted neovascularization in the peri-infarct area by paracrine activity rather than active transdifferentiation, resulting into cardioprotection as indicated by diminished scar formation and improved residual cardiac function. Aplnr knockdown in the bone marrow resulted in aggravation of myocardial ischemia–associated damage, which could not be rescued by apelin.

Conclusions: We conclude that apelin functions as a new and potent chemoattractant for circulating cKit+/Flk1+/Aplnr+ cells during early myocardial repair, providing myocardial protection against ischemic damage by improving neovascularization via paracine action.

Introduction

Several studies have reported the existence of circulating progenitor/stem cells originating from the bone marrow (BM). These circulating cells play a central role in postembryonic vasculogenesis, in analogy to angioblasts during embryonic development.1 Several reports have shown that in animal models of ischemia, progenitor/stem cells are mobilized and recruited to sites of ischemic neovascularization, including hind limb ischemia and myocardial infarction (MI), where they enhance the formation of new blood vessels by paracrine release of chemokines and angiotrophic factors and differentiation into endothelial cells.2–4 Together with the observation that bone marrow–derived progenitor/stem cell numbers are increased in patients after an acute MI,5,6 this suggests that these cells may play an essential role in the repair response mechanism after ischemia. The therapeutic potential of these cells in tissue preservation and/or regeneration after ischemia has also been demonstrated by several studies in which incorporation of these stem cells into the ischemic heart improved capillary density and residual contractile function.7–9

Additionally, several molecular mediators of the ischemic repair response, including vascular endothelial growth factor (VEGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), stromal cell–derived factor (SDF-1), and angiopoietin-1 (Ang-1), were shown to enhance the recruitment of circulating progenitor/stem cells and neovascularization in ischemic tissue.10–13 and some have already been used in clinical studies.14 Although the effectiveness of stem cell mobilization shows great promise for therapy,15 the process has proven to be extremely complex involving several cell subtypes and molecular signals that are not explained by the current identified mediators. Further characterization of the biology of these cells and the molecular mechanism that activates and recruits them is needed to design new therapeutic strategies.

Recently, we performed a genome-wide expression profile study in order to identify new genes involved in the regulation of vasculogenesis. Gene expression profiles of isolated angioblasts during early murine development were compared with the nonangioblast cells. Apelin receptor (Aplnr) was specifically expressed in angioblasts in the early phase of embryogenesis, which suggests a potential regulatory role in vasculogenesis in development.16 Aplnr, a member of the G-protein–coupled receptor family, and apelin, its natural ligand, are highly expressed in the cardiovascular system during development and adulthood.17,18

Loss of apelin or Aplnr in zebrafish and xenopus larvae resulted in defective intersomitic vessel formation and cardiac development during embryogenesis.19–21

Apelin signaling has been shown to be involved in the regulation of blood pressure,22,23 cardiac contractility,24,25 and cardiac differentiation.26,27 In addition, apelin/Aplnr signaling is associated with retinal blood vessel formation and tumor angiogenesis.17,28,29 The marked upregulation of both apelin and Aplnr after hypoxic insult in adult animals30,31 also suggest a role in ischemia-driven vasculogenesis.

Beneficial effects of apelin administration after MI have been reported previously,32,33 but this was performed in ischemia-reperfusion models and attributed to the direct cardioprotective actions involving the RISK pathway. A direct positive inotropic effect after MI has also been reported.34

In the present study, we sought to test the hypothesis that apelin and Aplnr are important regulators in the early mobilization and recruitment of cKit+/Flk1+ cells, specifically after MI. For this purpose, we used a permanent ligation model to exclude an effect of apelin on ischemia-reperfusion damage. In the first days after MI, apelin was shown to enhance the recruitment of specifically cKit+/Flk1+/Aplnr+ cells into the heart after MI. Apelin-recruited Aplnr+ cells were shown to improve myocardial neovascularization by a paracrine function and not by transdifferentiation. The presence of recruited cKit+/Flk1+/Aplnr+ cells after MI promoted a local proangiogenic cytokine profile, which resulted in neovascularization, less adverse remodeling, and subsequent preservation of cardiac function after MI.

Methods

This study was performed in accordance with the Council of Europe Convention (ETS123)/Directive (86/609/EEC) for the protection of vertebrate animals used for experimental and other scientific purposes and with the approval of the National and local Animal Care Committee.

Animals

Eight-week-old female C57BL/6-Tg(CAG-EGFP)1Osb/J mice (Jackson laboratories, Bar Harbor, ME). These mice express EGFP under the control of a chicken β-actin promoter and cytomegalovirus enhancer in all cells. Wild-type female C57BL/6J mice (age, 8 weeks) were obtained from Jackson laboratories and randomly assigned to the experimental groups.

In Vitro Viral Transduction of Donor Bone Marrow Cells

C57BL/6-Tg(CAG-EGFP)1Osb/J donors were euthanized by cervical dislocation and tibias and femurs were harvested and flushed with PBS to retrieve bone marrow. Single cell suspensions were transduced with sh.Aplnr or sh.sham (moi=15). After 48 hours of incubation, Aplnr protein and mRNA expression were verified by quantitative PCR and Western blot analysis as described below.

Bone Marrow Transplantation

C57BL/6 recipients were irradiated (2×4.5 Gy) and injected intravenously with 2.5×106 bone marrow cells, transduced with either sh.Aplnr, sh.sham, or EGFP as described.

The recipient mice were allowed to recover for 4 weeks under sterile conditions. The efficiency of BM repopulation was verified by flow cytometric analysis (BD FACSCanto, BD Biosciences, Erembodegem, Belgium) of EGFP expression in circulating and BM aspirate cells. BM functionality after transplantation was assessed using a Hemavet Mascot Multispecies Hematology System Counter 1500R (CDC Technology, Oxford, United Kingdom).

Surgical Procedures

Mice (age, 12 weeks) were weighed, sedated with 4% isoflurane, intubated, and pressure-control ventilated with O2-N2 (1:2, vol/vol) containing ≈2.5% isoflurane for anesthesia. MI was induced by permanent ligation of the left anterior descending coronary artery, as described before,35 with a 7-0 silk suture (BBraun, Aesculap AG&CO.KG, Tuttlingen, Germany). Hind limb ischemia (HLI) was induced by a permanent ligation of the femoral artery with a 6-0 silk suture (BBraun). Sham animals were subjected to the operation without arterial ligation. Every day for 5 days, animals were euthanized and tissues were harvested for subsequent analysis.

The mice were injected in the ischemic gastrocnemic muscle or myocardium with either 8 ng apelin-13 (Sigma) in 10 μL saline, or with saline only. Every day for 5 days, animals were euthanized and tissues were harvested for analysis.

In a different set of animals, we intravenously injected VEGFA, SDFα, apelin (all with a concentration of 8 ng/10 μL), or saline to study the effect on mobilization between the subsets.

To further assess the function of apelin/Aplnr signaling after myocardial ischemia, bone marrow from C57BL/6-Tg(CAG-EGFP)1Osb/J was harvested and infected by sh.sham or sh.Aplnr, as described above and subsequently transplanted into irradiated C57BL/6J wt mice. After the induction of MI, transplanted animals received either an intramyocardial injection of 8 ng apelin in 10 μL saline, saline, only or no injection. Animals were euthanized at 2, 6, or 14 days after MI. At 2 days, the animals were euthanized and the recruitment of cKit+/Flk1+ cells into heart was assessed by flow cytometry. At 5 days, the local production of angiogenic cytokines in the infarcted hearts was assessed. Other animals were used to isolated cKit+/Flk1+/Aplnr+ cells from the heart to study if these cells were producing angiogenic growth factors. At 14 days after MI, hemodynamic measurements were performed under general anesthesia, as described before.35 In brief, short- and long-axis view M-mode LV echocardiography (ALOKA, Prosound SSD-4000; Tokyo, Japan) was performed by a single blinded observer. From these images left ventricular end-diastolic (LVEDD) and end-systolic (LVESD) diameter were quantified, and fractional shortening calculated (FS=LVEDD−LVESD/LVEDD×100%) by 2 independent blinded observers.

In a subset of animals a 1.4F microtipped pressure transducer catheter (Millar Instruments, Houston, TX) was inserted into the LV. All data were recorded, digitized, and analyzed with a software program written in Matlab for determination of maximum rate of rise of LV pressure (LVdP/dtmax) and maximum rate of fall of LV pressure (LVdP/dtmin).

Left ventricular weight including septum and lung fluid weight were determined as surrogate markers for LV hypertrophy and manifest heart failure. Tibia length was used as a measure of age/growth of the mouse.

Flow Cytometric Analysis

Mononuclear cell suspensions of BM and blood were obtained by Ficoll density centrifugation and subsequent washing in RPMI-medium. Single cell suspensions of ventricles and gastrocnemic muscles were isolated by homogenization, washing, and filtration over a 40-μm Falcon cell strainer. Isolated cells were incubated with antibodies against Flk1 (Biotin-conjugated, BD Biosciences), cKit (APC-Cy7-conjugated, eBiosciences, Hatfield, United Kingdom), Sca1 (APC-conjugated, eBiosciences), Ter119, B220, CD11b, Gr-1, CD3, CD4, CD8 (PE-conjugated, eBiosciences), and Aplnr (LifeSpan Biosciences, Seattle, WA) for 15 minutes at 4°C. After washing, cells were incubated with goat anti-rabbit antibodies labeled with Alexa 488 (Invitrogen) and streptavidin (PeCy7-conjugated, eBiosciences) for 15 minutes at 4°C. 7AAD (BD biosciences) was used to select for cell viability. Flow cytometric analysis was performed on a FACSCanto (BD Biosciences) and subsequent data analysis by use of Flowjo software (Tree Star Inc, Ashland, OR). Reported values were normalized to naive control values, which were arbitrarily assigned the average value of 100. Using the same approach, cell sorting was performed on a FACSAria (BD Biosciences).

Histological Analysis

The left ventricles were embedded in paraffin and cut longitudinally into 5-μm sections and stained with standard hematoxylin and eosin and Masson trichrome to determine infarct size and cardiomyocyte cross-sectional area. To assess capillary density in the infarct borderzone, sections were also stained using isolectin. Briefly, sections were rehydrated and incubated with HRP-conjugated GS lectin (Sigma) in 5% BSA/PBS for 90 minutes at RT. Sections were washed in PBS and incubated for 5 minutes with NiDAB. Arteriolar density was assessed by staining with alkaline phosphatase-conjugated antibody against smooth muscle cell α-actin in 5% BSA/PBS for 90 minutes at RT. Sections were washed in PBS and incubated for 5 minutes with BCIP/NBT Alkaline Phosphatase Substrate (Vector Laboratories, Burlingame, CA).

After washing, sections are counterstained with nuclear fast red, dehydrated, and cover-slipped with Entellan (MERCK, Darmstadt, Germany). Data analysis was performed using a commercial image analysis system (Impak C, Clemex Technologies, Quebec, Canada).

For an extensive description of materials and methods, see the Online Data Supplement.

Statistical Analysis

Data were analyzed by 1-way or 2-way ANOVA, as appropriate, followed by individual unpaired Student t tests. Significance was accepted at a level of P<0.05. All data are presented as mean±SEM, unless otherwise stated.

Results

Aplnr Expression on Circulating Cells and Apelin Expression After Ischemia

To investigate the role of Aplnr and apelin in cell recruitment, Aplnr expression was assessed in different cell populations from the circulation by flow cytometry and quantitative PCR. Aplnr was highly expressed in all cKit+/Flk1+ circulating cells, showing a 9-fold higher mRNA expression and a 15-fold higher protein expression of Aplnr when compared with other circulating cell populations (Figure 1A through 1C). Serum levels of apelin were increased during the first 2 days after MI and gradually lowered during the following days. However, apelin levels failed to rise after HLI (Figure 1H). Myocardial apelin mRNA and protein expression were upregulated in the early days after the induction of MI, as compared with sham-operated animals (Figure 1D and 1F). In contrast, no increase of apelin mRNA or protein was noted in ischemic skeletal muscle after HLI (Figure 1E and 1G). These data suggest a possible role for Aplnr and apelin in the recruitment of the cKit+/Flk1+ cells specifically after MI.

Figure 1.
Figure 1.

Aplnr expression on circulating cells and apelin expression after ischemia. A, Aplnr mRNA expression in circulating cell populations (n=6 per group). B, Aplnr protein expression on circulating cell populations, expressed as mean fluorescent intensity (MFI) obtained by flow cytometry (n=4 per group). C, Representative flow cytometry data of Aplnr expression on circulating cells. Red colored dots represent cKit+/Flk1+ cells and black dots represent other circulating cells. The blue line indicates the maximum signal of unstained cells. D, Apelin mRNA was increased in the heart 2 days after MI in wild-type mice (n=6 per group). E, Apelin mRNA levels in striated muscle were not upregulated 2 days after HLI (n=6 per group). F, Two days after MI, apelin protein expression in the heart increased (n=6 per group). G, Apelin protein was not upregulated in skeletal muscle 2 days after HLI (n=6 per group). H, Circulating levels of apelin protein increased after MI but not after HLI (n=6 per group). *P<0.05 compared with sham-operated animals.

Cell Recruitment After Ischemia

To test if cKit+/Flk1+ cells were indeed specifically recruited to the infarcted heart, cell subsets were assessed by flow cytometry 3 days after the induction of MI and HLI. After HLI, Sca1+/Flk1+ cells but not cKit+/Flk1+ cells were increased 1.9-fold in the skeletal muscle and 1.7-fold in the circulation, when compared with control and sham-operated animals (Figure 2D, 2F, 2J, and 2L). However, this subset was not recruited to the myocardium and/or the circulation after myocardial ischemia (Figure 2J and 2K). The cKit+/Flk1+ cells showed opposite effects. After MI, cKit+/Flk1+cells but not Sca1+/Flk1+cells were increased by 2.1-fold in the myocardium as well as in the circulation compared with sham-operated animals and control animals (Figure 2D and 2E) but failed to respond to HLI (Figure 2F). As Aplnr was predominantly expressed in the cKit+/Flk1+ cell population, these findings point to a possible involvement of Aplnr/apelin signaling in this myocardial-specific repair response after ischemia. Interestingly, these cells were preferentially recruited to the borderzone of the infarct and not to other regions of the heart (Online Figure I).

Figure 2.
Figure 2.

Specific cKit+/Flk1+ cell recruitment and mobilization after myocardial and hind limb ischemia. A, B, and C, Representative flow cytometry data of blood (A), myocardium (B), and striated muscle (C). cKit+/Flk1+ cells were mobilized into blood and recruited to the myocardium 3 days after MI. D, E, and F, Quantification of cKit+/Flk1+ cells in blood (D), myocardium (E), and striated muscle (F) (n=8 per group). G, H, and I, Representative flow cytometry data of blood (G), heart (H), and striated muscle (I) for Sca1+/Flk1+ cells. Sca1+/Flk1+ cell numbers were specifically increased in the circulation and striated muscle after hind limb ischemia. J, K, and L, Quantification of Sca1+/Flk-1+ cells in blood (J), myocardium (K), and striated muscle (L) (n=8 per group). *P<0.05 versus naive animals.

Apelin Promotes Mobilization and Recruitment of cKit+/Flk1+ Cells

To investigate if apelin is capable of mobilizing and recruiting cKit+/Flk1+ cells, C57BL/6J mice received a single injection of apelin or saline in the ischemic myocardium or gastrocnemic muscle. During the following days, animals were euthanized and blood and tissues were analyzed for recruited cKit+/Flk1+ cells using flow cytometry. Apelin injection after MI resulted in an accelerated mobilization of cKit+/Flk1+ cells into the circulation, as compared with saline-injected or noninjected animals (Figure 3A). After apelin injection, cKit+/Flk1+ cell numbers were already enhanced from day 1 on and the peak values were reached at day 2, whereas in saline-injected or noninjected animals a similar peak level was reached after 3 days. After apelin injection, an increase of 54% in mobilized cKit+/Flk1+ cells in the circulation was noted at day 2 when compared with saline-injected or noninjected animals (Figure 3B and 3E). Intramyocardial injections of apelin increased infiltrating cKit+/Flk1+ cells by 52% when compared with saline-injected animals (Figure 3C and 3F). Likewise, cKit+/Flk1+ cells in gastrocnemic muscle increased after local apelin injection, although this was not statistically significant (P=0.071) when compared with controls (Figure 3D and 3G). Interestingly, Sca+/Flk1+ cells seem not responsive to apelin, whereas VEGFA and SDFα were able to mobilize these cells to the circulation (Online Figure II). However, whereas apelin could induce a mobilization response of the cKit+/Flk1+ cells, VEGFA and SDFα seem to have no effect on the mobilization of these cells. These data suggest that apelin functions in addition to VEGFA and SDFα by selectively promoting mobilization of cKit+/Flk1+ cells but not the Sca1+/Flk1+ cells to the circulation and promotes recruitment into ischemic tissue.

Figure 3.
Figure 3.

Apelin promotes cKit+/Flk1+ cell mobilization and recruitment. A, Quantification of circulating cKit+/Flk1+ cells during the 5 days after an MI. Apelin treatment accelerates the mobilization of cKit+/Flk1+ cells into the circulation. (n=6 per group). *P<0.05 compared with saline-injected animals and noninjected animals. B, C, and D, Representative flow cytometric analysis of blood (B), myocardium (C), and striated muscle (D) for cKit+/Flk1+ cells 2 days after treatment. Apelin promoted cKit+/Flk1+ mobilization and recruitment. E, F, and G, Quantification of cKit+/Flk1+ cells in blood (E), myocardium (F), and striated muscle (G) after apelin treatment (n=8 per group). *P<0.05 versus naïve animals.

Apelin Recruits cKit+/Flk1+/Aplnr+ Cells Into the Ischemic Heart After MI

To assess the effect of apelin-recruited cKit+/Flk1+ cells to the ischemic myocardium, unfractionated BM was harvested from C57BL/6-Tg(CAG-EGFP)1Osb/J mice. This BM, which ubiquitously expresses EGFP, was infected with a lentivirus encoding a shRNA targeting Aplnr (sh.Aplnr) or sham lentivirus, encoding nontargeting scrambled shRNA (sh.sham). Infected BM cells were subsequently transplanted into irradiated C57BL/6J wild-type recipients. Aplnr mRNA expression was decreased by 73% and protein expression was decreased by 71% in BM cells treated with sh.Aplnr, compared with controls (Figure 4A and 4B). After a repopulation period of 8 weeks, MI was induced and subsequently the animals either received an intramyocardial injection with apelin or saline into the infarcted heart, or no injection was given. To assess the effect of the Aplnr knockdown on the recruitment of cKit+/Flk1+ cells, animals were euthanized 2 days after the induction of MI. In sham-silenced animals, apelin injection resulted in an increase of cKit+/Flk1+ cell numbers (Figure 4C). Sca1+/Flk1+ and Lin+ cell numbers did not change after apelin injection in sham-silenced animals (Figure 4G and4H). Aplnr knockdown in BM cells resulted in a failure to recruit cKit+/Flk1+ cells into the myocardium after MI (Figure 4D). Sca1+/Flk1+ and Lin+ cell numbers did not differ between sh.sham- and sh.Aplnr-treated animals (Figure 4G and 4H), showing that endogenous apelin does not recruit these cells into the myocardium after a MI. Accordingly, in these animals, apelin injection with Aplnr-silenced BM failed to induce recruitment of cKit+/Flk1+ cells into the ischemic heart (Figure 4D).

Figure 4.
Figure 4.

Apelin is important in the recruitment of cKit+/Flk1+/Aplnr+ cells. A, Aplnr mRNA expression was reduced in BM after sh-Aplnr infection (n=4 per group). B, Aplnr protein expression in BM was downregulated after sh-Aplnr infection. C and D, Representative flow cytometry data of heart from a sham (C) and an Aplnr-silenced animal (D), 2 days after MI. C, Apelin enhanced the recruitment of cKit+/Flk1+ cells after MI in sham-silenced animals. D, Aplnr-silenced animals failed to promote recruitment of cKit+/Flk1+ cells after MI or apelin treatment. E and F, Representative flow cytometric analysis of myocardium for Sca+/Flk1+ (E) cells and Lin+ cells (F). Apelin treatment or Aplnr silencing did not change Sca+/Flk1+ and Lin+ cells recruitment. G and H, Quantification of Sca+/Flk1+ (G) and Lin+ cells (H) in the myocardium (n=8 per group). *P<0.05 versus control.

Apelin Recruitment of Aplnr+ Cells Preserves Left Ventricular Function After MI

Next, we assessed the effects of recruitment via Aplnr/apelin signaling after MI. As Aplnr has been shown to affect heart function via direct stimulation of cardiomyocytes and local ECs, we proceeded with the BM transplantation setup to exclude possible confounding effects. Four weeks after transplantation, BM transplant efficiency and functionality were assessed. Both transplantation groups showed that more than 99% cells from the BM and around 97% of the circulating cells were green fluorescent protein–positive (Online Figure III). The numbers WBCs, lymphocytes, neutrophils, and monocytes proved also to be not different between the 2 groups (Online Figure III). To assess the effect of recruited cKit+/Flk1+/Aplnr+ cells on myocardial function after an infarct, another 78 BM hybrid animals were subjected to an MI and subsequently received an intramyocardial injection of either apelin or saline, or no injection was given. One day after induction, 36 animals were euthanized to assess infarct size using Evans blue dye. Initial infarct size was not different between all experimental groups (Online Figure IV).

At 2 weeks after MI, left ventricular remodeling and function were measured by echocardiography, including left ventricular end-diastolic diameter (EDD) and fractional shortening (FS). All animals showed an expected decrease in FS on comparison with historical sham-operated control animals (39±2%).35 In sham-silenced animals, apelin injection resulted in a 48% improvement in FS, compared with saline-treated mice or control mice (Figure 5A and 5D), whereas EDD was similar between these groups (Figure 5C). Aplnr-knockdown in the BM resulted in a significant reduction of FS by -41%, compared with their sham-silenced controls. In Aplnr-silenced animals, apelin failed to improve FS compared with saline-injected animals and noninjected animals (Figure 5B and 5D), providing clear evidence that the improved cardiac function can fully attributed to the recruited BM derived cells and not to confounding effects of Aplnr activation in cardiomyocytes and resident endothelial cells (ECs). In addition, in sham-silenced mice, left ventricular weight and lung fluid accumulation was reduced in apelin-treated animals compared with control animals (Online Table I), suggesting an attenuation of myocardial hypertrophy with less pulmonary congestion. In contrast, Aplnr-knockdown animals without apelin treatment showed a trend toward an increase of left ventricular weight and lung fluid compared with their sham virus counterparts. Apelin injection failed to improve left ventricular and lung fluid weights in the Aplnr-silenced animals (Online Table I).

Figure 5.
Figure 5.

Apelin treatment and subsequent recruitment of cKit+/Flk1+/Aplnr+ cells improve residual left ventricular function after myocardial infarction. Representative M-mode echocardiographic images of sham-silenced animals (A) and Aplnr-silenced animals (B) 2 weeks after MI. Quantification of echocardiographic parameters: left ventricular end-diastolic diameter (EDD) (C) and fractional shortening (FS) (D) (n=7 per group). *P<0.05 versus sham saline and control. #P<0.05 versus corresponding sham.

A subset of animals was used to measure hemodynamic parameters, to assess cardiac function. In sham-silenced animals, apelin injection resulted in an significant increase of maximum rate of rise of LV pressure (LVdP/dtmax) and maximum rate of fall of LV pressure (LVdP/dtmin) compared with saline-treated mice (6596±367 mm Hg · s−1 versus 5654±265 mm Hg · s−1 and −6012±527 mm Hg · s−1 versus −5049±375 mm Hg · s−1: n=6 per group; P<0.05). Aplnr-knockdown in the BM resulted in a significant reduction of LVdP/dtmax and LVdP/dtmin (4792±466 mm Hg · s−1 and −3898±515 mm Hg · s−1: n=6 per group; P<0.05) as compared with saline-treated sh.sham animals. Apelin injection failed to improve these functional parameters (4920±247 mm Hg · s−1 and −3765±539 mm Hg · s−1: n=6 per group; P<0.05).

Taken together, these findings indicate that the contractile function after MI was improved by a repair mechanism initiated by apelin, by recruitment of cKit+/Flk1+/Aplnr+ cells from the BM and circulation.

Aplnr+ Cells Diminish Scar Formation After Myocardial Ischemia

The Aplnr-silenced BM recipients and control groups were further assessed on parameters of myocardial repair. Progressive left ventricular dysfunction after MI is caused by a combination of left ventricular dilation, compensatory cardiomyocyte hypertrophy, and scar formation. LV dilation was not attenuated by recruitment of cKit+/Flk1+/Aplnr+ cells after apelin treatment (Figure 5C). Myocyte cross-sectional area, as an indicator of cardiac hypertrophy, did not differ among the different groups at 14 days after MI (Figure 6E). However, apelin recruitment of Aplnr+ cells resulted in a reduction in epicardial infarct length of 22% and an increase of infarct thickness of 47% when compared with sh.sham virus-treated controls (Figure 6C and 6D). Silencing of endogenous Aplnr in the BM resulted in more extensive scar formation than their sham-silenced counterparts, suggesting that endogenous apelin and Aplnr also contributed to myocardial repair under normal conditions. Concordantly, in Aplnr knockdown animals, apelin treatment did not change epicardial infarct length or infarct thickness (Figure 6C and 6D), indicating that the remodeling effects of apelin requires Aplnr+ BM cells. Infarct measurements using Evans blue dye supported these findings. Apelin recruitment of Aplnr+ cells resulted in a reduction in infarct area compared with sh.sham virus–treated controls (Figure 6F). In contrast, animals in which Aplnr was silenced in the BM proved to have an increase of infarct area as compared with their sham-silenced counterparts (Figure 6F).

Figure 6.
Figure 6.

Apelin-recruited Aplnr+ cells reduce myocardial scar formation after MI. A and B, Representative Masson trichrome staining of longitudinal myocardial sections depicting scar tissue 2 weeks after MI. Reduced scar formation was observed in animals treated with apelin (A). Myocardial scar formation was enhanced in Aplnr-silenced animals, whereas apelin failed to reduce myocardial scar formation in these animals (B). C and D, Quantification of infarct dimensions: infarct thickness (C) and epicardial infarct length (D) (n=7 per group). Myocyte cross-sectional area (CSA) did not differ between animals (E) (n=7 per group). *P<0.05 versus sh.sham saline and control. #P<0.05 versus corresponding sh.sham. F, Infarct sizes determined using Evans blue infusion 2 weeks after MI induction. Infarct sizes were reduced in apelin-treated sh.sham animals. Aplnr-silenced animals showed enhanced infarct sizes, and apelin injection had no effect in these animals (n=5 per group). *P<0.05 versus sh.sham saline and control. #P<0.05 versus corresponding sh.sham.

Taken together, these findings suggest that apelin-recruited Aplnr+ cells diminish myocardial scar formation early after MI, subsequently resulting in a persistent improvement of myocardial function.

Apelin-Recruited Aplnr+ Cells Increase Neovascularization After Myocardial Ischemia

Apelin recruitment of cKit+/Flk1+/Aplnr+ cells increased capillary density in the infarct borderzone by 21%, compared with saline-treated animals in the sh.sham virus-treated mice (Figure 7A through 7C). In contrast, capillary densities in Aplnr-silenced groups were reduced by 9%, compared with the sham-silenced groups. Again, apelin treatment did not alter myocardial capillary density in Aplnr-silenced animals (Figure 7C). No effect on arteriolar density was observed between the experimental groups (Online Figure V).

Figure 7.
Figure 7.

Apelin treatment and subsequent recruitment of Aplnr+ cells enhance myocardial neovascularization after MI. A and B, Representative lectin staining of myocardial sections 14 days after sham or MI induction. Apelin increased capillary density in sham-silenced mice after MI (A). Aplnr-silenced animals showed diminished capillary density per field of view, whereas apelin treatment failed to increase the capillary density in these animals (B). C, Quantification of the capillary density. Sham-operated animals from the 2 BM transplantations are shown as reference. (n=7 per group). *P<0.05 versus sh.sham saline and control. #P<0.05 versus corresponding sh.sham.

Aplnr+ Cells Release Proangiogenic Cytokines

Although transgenic EGFP+ BM-derived cells were abundant in the peri-infarct zone after MI in the control groups with and without apelin treatment, immunohistological analysis using CD31 to identify the vasculature showed negligible numbers of EGFP+ incorporated in the neocapillaries (data not shown). We further hypothesized that recruited cKit+/Flk1+ cells may have a paracrine proangiogenic effect, rather than provide cardioprotection by active transdifferentiation into neovasculature. Therefore, the cytokine profile of heart samples were assed 6 days after MI. Treatment with apelin resulted in an upregulation of VEGFA protein expression compared with saline-treated animals (Figure 8A). In line with these observations, VEGFA in Aplnr-silenced recipients of Aplnr-silenced BM was significantly downregulated compared with sham-silenced animals (Figure 8A), indicating that recruitment of BM-derived cells by Aplnr/apelin interaction was responsible for the observed increase in local VEGFA levels. In addition, angiopoietin-2 (Ang-2) levels relative to Ang-1 levels (Ang-2/Ang-1 ratio) in apelin-treated animals were increased compared with the sh.sham-treated animals (Figure 8B through 8D). Myocardial Ang-2/Ang-1 ratio was markedly decreased in Aplnr-silenced animals (Figure 8B through 8D), suggestive of an antiangiogenic milieu. Aplnr-silenced animals were not responsive to apelin treatment and did not show a change in protein levels of any of these angiotrophic cytokines.

Figure 8.
Figure 8.

Aplnr+ cells promote the release of angiotrophic factors in the myocardium. A, VEGFA protein expression in the myocardium was increased in apelin-treated sham-silenced mice. Aplnr-silenced animals showed reduced VEGFA protein expression, as compared with sham virus-treated animals. Apelin treatment did not result in an increase of VEGFA protein in these animals. (n=5 per group). B and C, Myocardial expression of Ang-1 and Ang-2. D, Apelin treatment in sham-silenced mice increased Ang-2/Ang-1 ratio, whereas Aplnr-silenced animals showed inverse effects (n=5 per group). *P<0.05 versus sham saline. E through G, mRNA expression in isolated cKit+/Flk1+/Aplnr+ cells after MI. CKit+/Flk1+/Aplnr+ cells enhanced their mRNA expression of VEGFA (G) and Ang-2 (F) after MI, as compared with cKit+/Flk1+/Aplnr+ isolated from sham-operated hearts. The mRNA expression of Ang-1 (E) was decreased in these cells after MI as compared with cKit+/Flk1+/Aplnr+ isolated from sham-operated hearts (n=3 for each group). *P<0.05 versus sham.

To assess if cKit+/Flk1+/Aplnr+ cells were indeed capable of producing these growth factors, sham-operated and MI animals were euthanized 5 days after surgery, and these cells were isolated from the heart using a flow cytometric cell sorter. Analysis of the mRNA expression showed that after MI these cells enhanced the expression of VEGFA and Ang-2, as compared with sham-operated animals (Figure 8F and 8G). Ang-1 expression in these cells was diminished after MI as compared with sham-operated animals (Figure 8E). Moreover, mRNA expression levels of other known angiogenic and cardioprotective factors were also enhanced after MI (Online Figure VI). Interestingly, when cells isolated after MI were added to human umbilical vein endothelial cells (HUVECs) in an in vitro tube formation assay, an improvement in tube formation was observed (Online Figure VII). Taken together, these data point toward a role for Aplnr/apelin recruited BM-derived cells in providing a proangiogenic environment in affected heart areas after MI.

Discussion

In the current study, we have demonstrated that apelin-recruited Aplnr+ cells improve cardiac neovascularization and improve remodeling and cardiac function after MI. Apelin was specifically upregulated in the myocardium and circulation during the first days after MI but not after HLI, resulting in the recruitment of cKit+/Flk1+/Aplnr+ cells to the circulation and the ischemic heart. Apelin induced recruitment of this specific subpopulation resulted in an increase in proangiogenic factors at 6 days after MI and subsequently the capillary density, resulting in diminished cardiac scar formation with sustained cardiac function. Silencing of Aplnr in the BM abolished the recruitment of this population after MI, leading to a failure to mount a neovasculogenesis response, resulting in marked loss of cardiac function and enhanced scarring. These data demonstrate the important role of apelin and Aplnr+ cells in the orchestration of the myocardium-specific ischemic repair response.

Given the marked expression of Aplnr and its ligand apelin in angioblasts during mammalian embryonic development and the expression of apelin after hypoxia, we hypothesized that Aplnr/apelin signaling plays a central role in ischemia-driven neovascularization. Aplnr is highly expressed in the circulating cKit+/Flk1+ subpopulation. The ligand apelin was significantly upregulated particularly early after MI.36 Interestingly, this was not observed after HLI, suggesting that Aplnr/apelin signaling plays a specific role in a myocardium repair response.

Also cKit+/Flk1+/Aplnr+ cell numbers were increased in the circulation in response to myocardial ischemia but not in response to hind limb ischemia. In contrast, Sca1+/Flk1+ cells were recruited after HLI but failed to be recruited after MI. These data suggest a specific cell response for MI versus HLI. After a single intramyocardial injection, apelin induced an accelerated mobilization and homing of the cKit+/Flk1+/Aplnr+ cells not only into the myocardium but also in to striated muscles after a local injection of apelin into the ischemic hind limb. In contrast, cells with a lower Aplnr expression, like the Sca1+/Flk+ and Lin+ cells, failed to respond to apelin. These cells, however, showed a response to an injection of known chemotactic factors VEGFA or SDFα, whereas this was not the case for cKit+/Flk1+ cells, suggesting separate but additive recruitment pathways. These data further underline the remarkably potent but specific chemoattractive function of apelin, even in tissue in which its expression is normally not enhanced in response to ischemia.

Recruitment of cKit+/Flk1+/Aplnr+ cells by apelin promotes local neoangiogenesis resulting in preserved cardiac function and diminished adverse remodeling with reduced scar formation after MI. The importance of cell recruitment was earlier suggested in animals with impaired cKit function.7 In these animals, recruitment of cells after MI was diminished and resulted in pronounced scar formation with poor residual cardiac function.

Interestingly, recruited cells did not differentiate into endothelial cells. This suggests that these cKit+/Flk1+/Aplnr+ cells may express proangiogenic factors and locally stimulate resident ECs to initiate angiogenesis, consistent with earlier findings.37,38 In Aplnr-silenced hybrid mice, cKit+/Flk1+ cell recruitment was severely impaired after MI, resulting in diminished neovascularization and pronounced scar formation with poor residual cardiac function after MI. The recruitment of Sca+/Flk+ and Lin+ cells was not effected after Aplnr silencing, suggesting that apelin signaling does not play a crucial role in the mobilization of these cells. Importantly, apelin treatment in animals with Aplnr-silenced expression in BM cells failed to enhance the recruitment of the cKit+/Flk1+ cell population; nor did it change capillary density, suggesting that the beneficial effect is mainly mediated by recruitment of BM derived cells and not a local effect on residential cells.

Increased recruitment of cKit+/Flk1+/Aplnr+ cells by apelin injection was associated with an increase in local VEGFA expression and Ang-2/ Ang-1 ratio, whereas loss of Aplnr in the BM was associated with a decreased VEGFA expression and Ang-2/Ang-1 ratio. Ang-2 has been shown to block the quiescent signal of Ang-1 and to enhance the sensitivity of endothelial cells to VEGFA.39,40 Isolated cKit+/Flk1+/Aplnr+ cells proved to have an enhanced expression of VEGFA and Ang-2 and a reduced expression of Ang-1 after MI, indicating that they are at least in part responsible for the production of these cytokines. In line with our observations, another study showed that a mutation in the cKit gene, resulting in a dysfunctional protein, was associated with the reduced recruitment of cKit+ cells into the ischemic myocardium.7 This reduced recruitment resulted in a local decrease in VEGFA and Ang-2 production, suggesting a role of these cells in the release of the angiotrophic factors.

We also observed an enhanced mRNA expression of other known angiogenic and cardioprotective factors in these isolated cells after MI,41 indicating other protective mechanisms. In vitro experiments to study if cKit+/Flk1+/Aplnr+ cells could directly affect angiogenesis again indicated a stimulating effect of these cells. When HUVECs were cultured in combination with these cells in an in vitro tube formation assay, we observed an increase in the number of tubes and junction formed. These observations proved that cKit+/Flk1+/Aplnr+ can directly stimulate local angiogenesis.

Our data indicate a central role of Aplnr and apelin interaction in myocardial repair response to ischemia, by attracting a specific subset of cells toward the myocardium. Indeed, apelin expression is reduced in diabetes and hypercholesterolemia,42,43 2 known risk factors that have been associated with low circulating proangiogenic cell numbers with impaired function, resulting in an attenuated neoangiogenesis response.44,45 Moreover, physical exercise has been shown to promote the neoangiogenesis response by recruitment of circulating cells46 and has also been associated with increased apelin levels.47

In summary, the current study provides evidence for a central role of Aplnr/apelin interaction in the recruitment of cKit+/Flk1+/Aplnr+ cells toward the myocardium in the early phase after MI, where these cells enhance the local release of proangiogenic cytokines to promote neovascularization and limit myocardial damage and cardiac dysfunction. It is even possible that some growth factors produced by recruited cKit+/Flk1+/Aplnr+ cells mobilize and recruit other cell subset that repair the myocardium. To evaluate this interesting concept of possible interactions and dependence between subsets of cells in the MI condition, further research is needed. Other mediators, such as VEGFA, GM-CSF, SDF-1, and Ang-1 have been proven to enhance the number of circulating cells and neovascularization after ischemia,10⇓–13 but to our knowledge, none of these pathways is specific for the myocardial repair response. The apelin/Aplnr pathway may therefore represent a unique repair mechanism that may represent a new therapeutic approach to limit myocardial damage and dysfunction after MI.

Sources of Funding

C.C. is the recipient of the Dutch NWO-VENI grant. H.J.D. is the recipient of the Dutch NWO-VIDI grant.

Disclosures

None.

Footnotes

  • In June 2012, the average time from submission to first decision for all original research papers submitted to Circulation Research was 13.35 days.

  • The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/doi:10.1161/CIRCRESAHA.111.262097/-/DC1.

  • Non-standard Abbreviations and Acronyms

    Ang-1
    angiopoietin-1
    Ang-2
    angiopoietin-2
    Aplnr
    apelin receptor
    BM
    bone marrow
    cKit
    CD117, mast/stem cell growth factor receptor
    Flk1
    fetal liver kinase 1
    FS
    fractional shortening
    GM-CSF
    granulocyte-macrophage colony-stimulating factor
    HLI
    hind limb ischemia
    HUVECs
    human umbilical vein endothelial cells
    LV
    left ventricle
    LVdP/dtmax
    maximum rate of rise of LV pressure
    LVdP/dtmin
    maximum rate of fall of LV pressure
    LVEDD
    left ventricular end-diastolic diameter
    LVESD
    left ventricular end-systolic diameter
    MI
    myocardial infarction
    MFI
    mean fluorescent intensity
    Sca1
    stem cell antigen-1
    SDF
    stromal cell–derived factor
    VEGF
    vascular endothelial growth factor

  • Received December 7, 2011.
  • Revision received June 26, 2012.
  • Accepted July 2, 2012.

References

  1. 1.↵
    1. Carmeliet P
    . Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000; 6: 389– 395.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Asahara T,
    2. Masuda H,
    3. Takahashi T,
    4. Kalka C,
    5. Pastore C,
    6. Silver M,
    7. Kearne M,
    8. Magner M,
    9. Isner JM
    . Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85: 221– 228.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Crosby JR,
    2. Kaminski WE,
    3. Schatteman G,
    4. Martin PJ,
    5. Raines EW,
    6. Seifert RA,
    7. Bowen-Pope DF
    . Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res. 2000; 87: 728– 730.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kalka C,
    2. Masuda H,
    3. Takahashi T,
    4. Kalka-Moll WM,
    5. Silver M,
    6. Kearney M,
    7. Li T,
    8. Isner JM,
    9. Asahara T
    . Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000; 97: 3422– 3427.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Shintani S,
    2. Murohara T,
    3. Ikeda H,
    4. Ueno T,
    5. Honma T,
    6. Katoh A,
    7. Sasaki K,
    8. Shimada T,
    9. Oike Y,
    10. Imaizumi T
    . Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001; 103: 2776– 2779.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Leone AM,
    2. Rutella S,
    3. Bonanno G,
    4. Abbate A,
    5. Rebuzzi AG,
    6. Giovannini S,
    7. Lombardi M,
    8. Galiuto L,
    9. Liuzzo G,
    10. Andreotti F,
    11. Lanza GA,
    12. Contemi AM,
    13. Leone G,
    14. Crea F
    . Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J. 2005; 26: 1196– 1204.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Fazel S,
    2. Cimini M,
    3. Chen L,
    4. Li S,
    5. Angoulvant D,
    6. Fedak P,
    7. Verma S,
    8. Weisel RD,
    9. Keating A,
    10. Li RK
    . Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest. 2006; 116: 1865– 1877.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Kawamoto A,
    2. Gwon HC,
    3. Iwaguro H,
    4. Yamaguchi JI,
    5. Uchida S,
    6. Masuda H,
    7. Silver M,
    8. Ma H,
    9. Kearney M,
    10. Isner JM,
    11. Asahara T
    . Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001; 103: 634– 637.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Kocher AA,
    2. Schuster MD,
    3. Szabolcs MJ,
    4. Takuma S,
    5. Burkhoff D,
    6. Wang J,
    7. Homma S,
    8. Edwards NM,
    9. Itescu S
    . Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001; 7: 430– 436.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Hattori K,
    2. Dias S,
    3. Heissig B,
    4. Hackett NR,
    5. Lyden D,
    6. Tateno M,
    7. Hicklin DJ,
    8. Zhu Z,
    9. Witte L,
    10. Crystal RG,
    11. Moore MA,
    12. Rafii S
    . Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001; 193: 1005– 1014.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Moore MA,
    2. Hattori K,
    3. Heissig B,
    4. Shieh JH,
    5. Dias S,
    6. Crystal RG,
    7. Rafii S
    . Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci. 2001; 938: 36– 45.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Rafii S,
    2. Heissig B,
    3. Hattori K
    . Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther. 2002; 9: 631– 641.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Takahashi T,
    2. Kalka C,
    3. Masuda H,
    4. Chen D,
    5. Silver M,
    6. Kearney M,
    7. Magner M,
    8. Isner JM,
    9. Asahara T
    . Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999; 5: 434– 438.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Ripa RS,
    2. Wang Y,
    3. Jorgensen E,
    4. Johnsen HE,
    5. Hesse B,
    6. Kastrup J
    . Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J. 2006; 27: 1785– 1792.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Boy S,
    2. Sauerbruch S,
    3. Kraemer M,
    4. Schormann T,
    5. Schlachetzki F,
    6. Schuierer G,
    7. Luerding R,
    8. Hennemann B,
    9. Orso E,
    10. Dabringhaus A,
    11. Winkler J,
    12. Bogdahn U
    . Mobilisation of hematopoietic CD34+ precursor cells in patients with acute stroke is safe–results of an open-labeled non randomized phase I/II trial. PloS One. 2011; 6: e23099.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Herpers R
    . Genetic regulation of vascular development [PhD thesis]. Rotterdam: Experimental Cardiology, Erasmus University Rotterdam; 2010.
  17. 17.↵
    1. Kalin RE,
    2. Kretz MP,
    3. Meyer AM,
    4. Kispert A,
    5. Heppner FL,
    6. Brandli AW
    . Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol. 2007; 305: 599– 614.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Kleinz MJ,
    2. Skepper JN,
    3. Davenport AP
    . Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005; 126: 233– 240.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Cox CM,
    2. D'Agostino SL,
    3. Miller MK,
    4. Heimark RL,
    5. Krieg PA
    . Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol. 2006; 296: 177– 189.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Inui M,
    2. Fukui A,
    3. Ito Y,
    4. Asashima M
    . Xapelin and Xmsr are required for cardiovascular development in Xenopus laevis. Dev Biol. 2006; 298: 188– 200.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Zeng XX,
    2. Wilm TP,
    3. Sepich DS,
    4. Solnica-Krezel L
    . Apelin and its receptor control heart field formation during zebrafish gastrulation. Dev Cell. 2007; 12: 391– 402.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Tatemoto K,
    2. Takayama K,
    3. Zou MX,
    4. Kumaki I,
    5. Zhang W,
    6. Kumano K,
    7. Fujimiya M
    . The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001; 99: 87– 92.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Lee DK,
    2. Cheng R,
    3. Nguyen T,
    4. Fan T,
    5. Kariyawasam AP,
    6. Liu Y,
    7. Osmond DH,
    8. George SR,
    9. O'Dowd BF
    . Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000; 74: 34– 41.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Szokodi I,
    2. Tavi P,
    3. Foldes G,
    4. Voutilainen-Myllyla S,
    5. Ilves M,
    6. Tokola H,
    7. Pikkarainen S,
    8. Piuhola J,
    9. Rysa J,
    10. Toth M,
    11. Ruskoaho H
    . Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002; 91: 434– 440.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Quertermous T
    . Apelin and its g protein-coupled receptor regulate cardiac development as well as cardiac function. Dev Cell. 2007; 12: 319– 320.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. D'Aniello C,
    2. Lonardo E,
    3. Iaconis S,
    4. Guardiola O,
    5. Liguoro AM,
    6. Liguori GL,
    7. Autiero M,
    8. Carmeliet P,
    9. Minchiotti G
    . G protein-coupled receptor APJ and its ligand apelin act downstream of Cripto to specify embryonic stem cells toward the cardiac lineage through extracellular signal-regulated kinase/p70S6 kinase signaling pathway. Circ Res. 2009; 105: 231– 238.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Gao LR,
    2. Zhang NK,
    3. Bai J,
    4. Ding QA,
    5. Wang ZG,
    6. Zhu ZM,
    7. Fei YX,
    8. Yang Y,
    9. Xu RY,
    10. Chen Y
    . The apelin-APJ pathway exists in cardiomyogenic cells derived from mesenchymal stem cells in vitro and in vivo. Cell Transplant. 2010; 19: 949– 958.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Kasai A,
    2. Shintani N,
    3. Kato H,
    4. Matsuda S,
    5. Gomi F,
    6. Haba R,
    7. Hashimoto H,
    8. Kakuda M,
    9. Tano Y,
    10. Baba A
    . Retardation of retinal vascular development in apelin-deficient mice. Arterioscler Thromb Vasc Biol. 2008; 10: 1717– 1722.
    OpenUrl
  29. 29.↵
    1. Kasai A,
    2. Shintani N,
    3. Oda M,
    4. Kakuda M,
    5. Hashimoto H,
    6. Matsuda T,
    7. Hinuma S,
    8. Baba A
    . Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun. 2004; 325: 395– 400.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Eyries M,
    2. Siegfried G,
    3. Ciumas M,
    4. Montagne K,
    5. Agrapart M,
    6. Lebrin F,
    7. Soubrier F
    . Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res. 2008; 103: 432– 440.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Kunduzova O,
    2. Alet N,
    3. Delesque-Touchard N,
    4. Millet L,
    5. Castan-Laurell I,
    6. Muller C,
    7. Dray C,
    8. Schaeffer P,
    9. Herault JP,
    10. Savi P,
    11. Bono F,
    12. Valet P
    . Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes. FASEB J. 2008; 22: 4146– 4153.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Zeng XJ,
    2. Zhang LK,
    3. Wang HX,
    4. Lu LQ,
    5. Ma LQ,
    6. Tang CS
    . Apelin protects heart against ischemia/reperfusion injury in rat. Peptides. 2009; 30: 1144– 1152.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Simpkin JC,
    2. Yellon DM,
    3. Davidson SM,
    4. Lim SY,
    5. Wynne AM,
    6. Smith CC
    . Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol. 2007; 102: 518– 528.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Berry MF,
    2. Pirolli TJ,
    3. Jayasankar V,
    4. Burdick J,
    5. Morine KJ,
    6. Gardner TJ,
    7. Woo YJ
    . Apelin has in vivo inotropic effects on normal and failing hearts. Circulation. 2004; 110: II187– II193.
    OpenUrlPubMed
  35. 35.↵
    1. de Waard MC,
    2. van der Velden J,
    3. Bito V,
    4. Ozdemir S,
    5. Biesmans L,
    6. Boontje NM,
    7. Dekkers DH,
    8. Schoonderwoerd K,
    9. Schuurbiers HC,
    10. de Crom R,
    11. Stienen GJ,
    12. Sipido KR,
    13. Lamers JM,
    14. Duncker DJ
    . Early exercise training normalizes myofilament function and attenuates left ventricular pump dysfunction in mice with a large myocardial infarction. Circ Res. 2007; 100: 1079– 1088.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Ronkainen VP,
    2. Ronkainen JJ,
    3. Hanninen SL,
    4. Leskinen H,
    5. Ruas JL,
    6. Pereira T,
    7. Poellinger L,
    8. Vuolteenaho O,
    9. Tavi P
    . Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J. 2007; 21: 1821– 1830.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Urbich C,
    2. Aicher A,
    3. Heeschen C,
    4. Dernbach E,
    5. Hofmann WK,
    6. Zeiher AM,
    7. Dimmeler S
    . Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol. 2005; 39: 733– 742.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Urbich C,
    2. Dimmeler S
    . Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004; 95: 343– 353.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Asahara T,
    2. Chen D,
    3. Takahashi T,
    4. Fujikawa K,
    5. Kearney M,
    6. Magner M,
    7. Yancopoulos GD,
    8. Isner JM
    . Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998; 83: 233– 240.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Hanahan D
    . Signaling vascular morphogenesis and maintenance. Science. 1997; 277: 48– 50.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Burchfield JS,
    2. Dimmeler S
    . Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogene Tiss Repair. 2008; 1: 1– 4.
    OpenUrlCrossRef
  42. 42.↵
    1. Erdem G,
    2. Dogru T,
    3. Tasci I,
    4. Sonmez A,
    5. Tapan S
    . Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008; 116: 289– 292.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Tasci I,
    2. Dogru T,
    3. Naharci I,
    4. Erdem G,
    5. Yilmaz MI,
    6. Sonmez A,
    7. Bingol N,
    8. Kilic S,
    9. Bingol S,
    10. Erikci S
    . Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes. 2007; 115: 428– 432.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Chen JZ,
    2. Zhang FR,
    3. Tao QM,
    4. Wang XX,
    5. Zhu JH,
    6. Zhu JH
    . Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin Sci. 2004; 107: 273– 280.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Loomans CJ,
    2. de Koning EJ,
    3. Staal FJ,
    4. Rookmaaker MB,
    5. Verseyden C,
    6. de Boer HC,
    7. Verhaar MC,
    8. Braam B,
    9. Rabelink TJ,
    10. van Zonneveld AJ
    . Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2004; 53: 195– 199.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Laufs U,
    2. Werner N,
    3. Link A,
    4. Endres M,
    5. Wassmann S,
    6. Jurgens K,
    7. Miche E,
    8. Bohm M,
    9. Nickenig G
    . Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation. 2004; 109: 220– 226.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Zhang J,
    2. Ren CX,
    3. Qi YF,
    4. Lou LX,
    5. Chen L,
    6. Zhang LK,
    7. Wang X,
    8. Tang C
    . Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci. 2006; 79: 1153– 1159.
    OpenUrlCrossRefPubMed

Novelty and Significance

What Is Known?

  • Transplantation or mobilization of stem cells can be used to repair the damage caused by a myocardial infarction (MI).

  • Neovascularization is one of the key processes to repair the heart after an infarction.

  • Apelin signaling is important for a wide range of vascular actions, including angiogenesis, cardiac contractility, and blood pressure regulation.

What New Information Does This Article Contribute?

  • Apelin functions as a specific chemoattractant for a potent sub population of bone marrow–derived cells that are recruited early after MI via apelin/apelin receptor (Aplnr) binding.

  • The attracted circulating Aplnr+ cells improve local neovascularization and subsequently diminish scar formation and benefit cardiac function after MI.

Myocardial infarction causes irreversible damage to cardiac tissue, which is difficult to repair. Therefore, new therapies to regenerate cardiac tissue are needed. Results of recent attempts to repair the damage after MI are encouraging, but the approach needs further improvement. To optimize cell therapy, we need a better understanding of the environmental cues that are required for stem cell trafficking to define the genetic and cellular mechanisms involved in myocardial repair. In the present study, we found that in mice the ligand apelin mobilizes and recruits Aplnr+ bone marrow–derived cells to the heart after MI. These recruited cells secrete growth factors that locally stimulate neovascularization and subsequently improve cardiac function and diminish infarct size. These findings suggest that apelin functions as a new and potent chemoattractant for bone marrow–derived Aplnr+ cells early during myocardial repair. On the basis of these observations, we conclude that the apelin/Aplnr pathway may represent a unique repair mechanism, which could be a target for a new therapeutic approach to stem cell therapy for myocardial repair and regeneration.

View Abstract

This Issue

Jump to

Article Tools

Share this Article

  • Email
  • Apelin Enhances Cardiac Neovascularization After Myocardial Infarction by Recruiting Aplnr+ Circulating CellsNovelty and Significance
    Dennie Tempel, Martine de Boer, Elza D. van Deel, Remco A. Haasdijk, Dirk J. Duncker, Caroline Cheng, Stefan Schulte-Merker and Henricus J. Duckers
    Circulation Research. 2012;111:585-598, originally published August 16, 2012
    https://doi.org/10.1161/CIRCRESAHA.111.262097
    Permalink:
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Subjects